Yuji Koichiro, Miyakoshi Shigesaburo, Kato Daisuke, Miura Yuji, Myojo Tomohiro, Murashige Naoko, Kishi Yukiko, Kobayashi Kazuhiro, Kusumi Eiji, Narimatsu Hiroto, Hamaki Tamae, Matsumura Tomoko, Kami Masahiro, Fukuda Takahiro, Masuo Shigeru, Masuoka Kazuhiro, Wake Atsushi, Ueyama Junichi, Yoneyama Akiko, Miyamoto Ko, Nagoshi Haruhisa, Matsuzaki Michio, Morinaga Shinichi, Muto Yoshitomo, Takeue Yoichi, Taniguchi Shuichi
Department of Hematology, Toranomon Hospital, Toranomon, Tokyo, Japan.
Biol Blood Marrow Transplant. 2005 Apr;11(4):314-8. doi: 10.1016/j.bbmt.2005.01.012.
We report the results of reduced-intensity unrelated cord blood transplantation (RI-UCBT) in patients with advanced malignant lymphoma. Twenty patients (median age, 46.5 years; range, 27-66 years) underwent RI-UCBT with a preparative regimen consisting of fludarabine 125 mg/m2 , melphalan 80 mg/m 2 , and 4 Gy of total body irradiation. The median infused total cell dose was 2.75 x 10(7)/kg (range, 2.3-3.4 x 10(7)/kg). Graft-versus-host disease (GVHD) prophylaxis was composed of cyclosporine or tacrolimus alone. Fifteen patients achieved primary neutrophil engraftment after a median of 20 days. Eight patients developed grade II to IV acute GVHD, and 2 developed chronic GVHD. Of the 16 patients with evaluable disease, 10 achieved a complete response. Primary disease recurred in 1 patient, and transplant-related mortality within 100 days occurred in 8 of 20 patients. The estimated 1-year probability of progression-free survival was 50%. These data suggest that RI-UCBT is a feasible option for patients with refractory lymphoma who lack an HLA-matched donor.
我们报告了降低强度的非亲属脐血移植（RI-UCBT）治疗晚期恶性淋巴瘤患者的结果。20例患者（中位年龄46.5岁；范围27 - 66岁）接受了RI-UCBT，预处理方案包括氟达拉滨125 mg/m²、美法仑80 mg/m²和4 Gy全身照射。输注的总细胞剂量中位数为2.75×10⁷/kg（范围2.3 - 3.4×10⁷/kg）。移植物抗宿主病（GVHD）预防仅由环孢素或他克莫司组成。15例患者在中位20天后实现了中性粒细胞初步植入。8例患者发生了II至IV级急性GVHD，2例发生了慢性GVHD。在16例可评估疾病的患者中，10例实现了完全缓解。1例患者原发疾病复发，20例患者中有8例在100天内发生了移植相关死亡。估计的1年无进展生存率为50%。这些数据表明，RI-UCBT对于缺乏HLA匹配供体的难治性淋巴瘤患者是一种可行的选择。
